Nuclear Medicine Communications **10**, 919–931 (1989)

INDEXES TO VOLUME 10

Subject index

The abbreviation (E) after a page number indicates an editorial article, (N) indicates a newsletter, (C) indicates a correspondence and (A) indicates a conference abstract.

Bone
A simple method of identifying loosening or infection of hip protheses in nuclear medicine, 551
Bone scanning for metastases: are limb images necessary?, 258(A)
Bone scans of osteoarthritic hands correlate with size of growing osteophytes, 233(A)
Bone marrow scintigraphy with $^{99}Tc^{m}$-nanocolloids in patients with malignant disease; a preliminary report, 374(A)
Bone scintigraphy following ^{89}Sr palliation of disseminated prostatic carcinoma, 234(A)
Bone secondaries in breast cancer; the solitary metastasis, 235(A)
Colloid scanning as an adjunct to white cell scanning in osteomyelitis, 236(A)
Considerations for improving the performance of dual photon bone absorptiometers, 221(A)
Controversies in nuclear medicine, 765
Results from the first 212 patients studied using QDR bone densitometry, 217(A)
Role of thallium-201 in the diagnosis of solitary bone lesions, 477
Scintigraphy of inflammation with non-specific tracers in orthopedic indicators, 218(A)
Serial bone scans in Paget's disease: changes with and without treatment, 234(A)
Strontium-89 therapy in disseminated prostatic carcinoma, 224(A)
X-ray based DPA; a significant advance?, 216(A)
Yttrium-90-EDTMP: a bone seeking radiotherapeutic agent, 224(A)

Brain
A comparison of $^{99}Tc^{m}$-HMPAO SPECT with CT and MRI in patients with closed head injury, 254(A)
An assessment of the role of ^{123}I-N-isopropyl-p-iodoamphetamine with single-photon emission computed tomography in the diagnosis of stroke and Alzheimer's disease, 271
Brain perfusion defect size in SPECT predicts outcome in cerebral infarction, 891
Brain SPECT in neonates, 255(A)
Five patients with Rasmussen's syndrome investigated by single-photon-emission computed tomography, 5
Focal temporal lobe epilepsy; oblique reconstruction and slice re-orientation improves HMPAO/SPET analysis, 231(A)
Intracellular localization of $^{99}Tc^{m}$-d, l-HMPAO and ^{201}Tl-DDC in rat brain, 459
Investigations of brain tumours with $^{99}TC^{m}$-HMPAO SPECT, 325
Local cerebral glucose abnormalities in mild closed head injured patients with cognitive impairments, 335
One-year follow-up of dementia of Alzheimer type (DAT) patients: clinical and rCBF/SPET correlations, 232(A)
Scuba diving: a sport of leisure, pleasure and covert brain damage, 256(A)
Semi-automatic quantification of regional cerebral perfusion in dementia using $^{99}TC^{m}$-HMPAO and single photon emission tomography, 254(A)
SPECT of rCBF and rCBV combined with rCPR and radionuclide angiography (RNA), 231(A)
Stereographic projection of SPECT brain images, 233(A)

0143–3636/89 $03.00+.12 *© 1989 Chapman and Hall Ltd.*

$^{99}Tc^{m}$-HMPAO brain SPECT in congenital dysphasia, 255(A)
$^{99}Tc^{m}$-HMPAO SPET and cerebral blood flow: a study of CO_2 reactivity, 609
The effect of ROI size and plane of reconstruction on HMPAO/SPET rCBF studies, 253(A)
Uncharacteristic distribution of $^{99}Tc^{m}$-HMPAO in Alzheimer's disease (AD), 232(A)

Cardiac

A new method of assessing forward ejection fraction from first pass radionuclide studies, 212(A)
A new, simple and precise method for determination of right ventricular forward ejection fraction in first-pass radionuclide cardiography, 879
Assessment of the effect of interpolative background subtraction methods on the quantitation of myocardial uptake of $^{99}Tc^{m}$-MIBI using software phantoms, 249(A)
Caffeine reduces dipyridamole induced myocardial ischaemia, 207(A)
Cardiac imaging with $^{99}Tc^{m}$-isonitriles; practical experiences from the first 100 patients, 262(A)
Detection of viable myocardium with ^{201}Tl, the role of late redistribution after overnight rest, 207(A)
Diagnostic accuracy of $^{99}Tc^{m}$-MIBI and ^{201}Tl-SPET in coronary artery disease: a comparison, 209(A)
Diagnosis of coronary artery disease using thallium imaging: tomographic versus planar imaging, 401
Early isonitrile SPECT in acute myocardial infarction: feasibility and results before and after fibrinolysis, 539
Evidence of myocardial necrosis in the absence of diagnostic ECG changes, 205(A)
Evidence of redistribution of $^{99}Tc^{m}$-MIBI in human subjects, 210(A)
First pass ventriculography and perfusion imaging with $^{99}Tc^{m}$-MIBI in planning intervention therapy for coronary artery disease; a rational approach?, 205(A)
How important is the amplitude image in cardiac phase/amplitude imaging?, 212(A)
Immunoscintigraphy of damaged myocardium using radiolabelled cardiac troponin-1 antibodies, 371(A)
Improving diagnostic quality with end diastolic $^{99}Tc^{m}$ hexakis 2-methoxyisobutyl isonitrile images, 210(A)
Krypton-81m gated imaging for assessment of right ventricular function, 371(A)
Manual v. automatic delineation of left ventricle (LV) in multigated cardiac studies, 261(A)
Methods of background subtraction in myocardial perfusion imaging with thallium-201: a comparative study in the presents of an artefact, 415
Myocardial gated tomoscintigraphy with $^{99}Tc^{m}$ methoxy-isobutyl-isonitrile (mibi): regional and temporal activity curve analysis, 723
Myocardial infarction imaging, 699(E)
Myocardial infarction imaging by planar and tomographic radionuclide ventriculography, 206(A)
Myocardial perfusion imaging in man using new $^{99}Tc^{m}$-labelled diphosphine complexes, 245(A)
Noninvasive prediction of mortality in myocardial infarction, 205(A)
Patient care, a comparison between myocardial imaging with ^{201}Tl and $^{99}Tc^{m}$-MIBI, 262(A)
Perfusion patterns in syndrome X, 213(A)
Projection and the measurement of left ventricular end diastolic volume from first pass studies, 211(A)
Reproducibility of semi-automated methods for analysing left ventricular function, 261(A)
Right ventricular myocardial uptake of $^{99}Tc^{m}$-MIBI, 210(A)
Survey of nuclear cardiological practice in Great Britain in 1988, 258(A)
The clinical role of myocardial perfusion imaging, 311(E)

The economical use of $^{99}Tc^{m}$-hexamibi kits, 247(A)
The evaluation of right ventricular function in acute myocardial infarction by xenon-133, 35
The multislice cylinder: a new approach to quantification of cardiac single photon emission tomography, 409
The noninvasive diagnosis of obliterative bronchiolitis following heart-lung transplantation, 213(A)
^{201}Tl in the assessment of single vessel coronary artery disease, 208(A)
Use of radionuclide ventriculography to assess the effects of coronary angioplasty post thrombolysis, 206(A)
Validation of the cardioscint: a new system for continuous monitoring of left ventricular function, 211(A)
Ventricular systolic and diastolic rate indices in patients with either normal or low resting left ventricular ejection fraction, 669
Which factors determine ischaemia detection by $^{99}Tc^{m}$-MIBI?, 209(A)

Endocrine

A low cost system for the dispensing and administration of sodium iodide ^{131}I therapy solutions, 259(A)
Effect of Lugol's iodine on the vascularity of thyroid gland in hyperthyroidism, 679
^{123}I labelling of phenothiazinium dyes for parathyroid localization, 243(A)
Immunoscintigraphy of pelvic endometriosis, 223(A)
Low sensitivity of parathyroid scintigraphy for upper pole adenomata and a new subtraction method to improve their detectability, 220(A)
New tracers for the imaging of the medullary thyroid carcinoma, 285
$^{99}Tc^{m}$-RP30; a new agent for parathyroid imaging, 220(A)
$^{99}Tc^{m}$ sestamibi – a new agent for parathyroid imaging, 791
The pyramidal lobe: a scintigraphic assessment, 685
Which therapy for Grave's hyperthyroidism in children?, 855(E)

Gastrointestinal

Can $^{99}Tc^{m}$-labelled RBC scintigraphy alone help in the investigation of unexplained gastrointestinal haemorrhage?, 230(A)
Carbon-14 urea breath test for the identification of Campylobacter pylori, 369(A)
Clinical use of a radiation detecting probe for the intra-operative localization of colorectal cancers and metastases, 222(A)
Colorectal cancer radioimmunoscintigraphy, RIS, with a $^{99}Tc^{m}$-labelled monoclonal antibody, PR1A3, 221(A)
Compressed images of the antrum for assessing gastric motility, 370(A)
Detection of intra-abdominal sepsis with 4 h $^{99}Tc^{m}$-HMPAO leucocyte images, 235(A)
Evaluation of oesophageal transit in patients with minor peptic oesophagitis, 161
Gallbladder function and fasting enterogastric bile reflux, 193
Gastric emptying after partial gastrectomy without vagotomy, 715
Gastric emptying of liquid meals: validation of the gamma camera technique, 353
Gastro intestinal cancer localization with ^{111}In-labelled monoclonal antibodies (MoAb): can ^{111}In chelating agents improve the results obtained?, 246(A)
Immunoscintigraphy (IS) in patients with colorectal cancer recurrences, 222(A)
^{111}In leucocyte scintigraphy in assessing patients with Crohn's disease, unresponsive to therapy, 237(A)
^{32}P kinetics in polycythaemia vera – is bremsstrahlung imaging of any value?, 377(A)
Pouch inflammation following restorative proctocolectomy: an appraisal of ^{111}In labelled granulocytes, 238

Quantification of whole body granulocyte excretion in inflammatory bowel disease, 267(A)
$^{99}Tc^{m}$ nanocolloid and ^{111}In leucocyte scintigraphy in inflammatory bowel disease, 236(A)
The effect of eating on transit time through the small intestine, 45
Use of $^{99}Tc^{m}$ nanocolloid for locating inflammatory bowel disease and abdominal abcesses, 237(A)

Haematology and infection

A comparison between visual and quantitative analysis in a prospective evaluation of labelled ^{111}In-leucocyte imaging in vascular infection, 487
Are platelet kinetic studies helpful in assessing idiopathic thrombocytopenia?, 376(A)
A simple method of identifying loosening or infection of hip protheses in nuclear medicine, 551
Body surface dosimetry following re-injections of ^{111}In-leucocytes, 497
Cell labelling with $^{99}Tc^{m}$ d and HMPAO, 374(A)
Colloidal carriers for targeting to the bone marrow, 243(A)
Colloid scanning as an adjunct to white cell scanning in osteomyelitis, 236(A)
Comparison of ultrasonography and ^{111}In leucocyte imaging and ultrasonography in acute pancreatitis, 266(A)
Detection of intra-abdominal sepsis with 4 h $^{99}Tc^{m}$-HMPAO leucocyte images, 235(A)
Does heparin augment thrombolysis by tissue plasminogen activator (TPA)? – an in vitro assessment using ^{125}I-fibrinogen, 378(A)
Does plasma fat, viscosity or erythrocyte sedimentation rate affect the radiolabelling of leucocytes?, 244(A)
Dosimetry of an indium-111 anti-T lymphocyte monoclonal antibody in a rat model and its implications in man, 246(A)
Experience with $^{99}Tc^{m}$-HMPAO labelled leucocytes in a district general hospital, 244(A)
Immunoscintigraphy (IS) with ^{123}I- and $^{99}Tc^{m}$-labelled granulocytes antibody (Ab), 266(A)
^{111}In leucocyte scintigraphy in assessing patients with Crohn's disease, unresponsive to therapy, 237(A)
^{111}In platelet deposition following peripheral arterial thrombolysis, 376(A)
Indium white cell imaging to detect abscesses in critically ill patients, 372(A)
In vivo imaging and quantitation of renal transplant rejection using indium-111 labelled anti-lymphocyte and anti-MHC class I and II monoclonal antibodies in a rat model, 264(A)
Kinetics of ^{111}In chloride in chronic myelogenous leukemia, 817
Neutrophil activation during cell separation procedures, 901
Pouch inflammation following restorative proctocolectomy: an appraisal of ^{111}In labelled granulocytes, 238(A)
Quantification of whole body granulocyte excretion in inflammatory bowel disease, 267(A)
Radiotherapy by $^{114}In^{m}$ labelled lymphocytes combined with chemotherapy in rat leukaemia model, 226(A)
Scintigraphy of inflammation with non-specific tracers in orthopedic indications, 218(A)
Sequential imaging of post-operative thrombus with a platelet specific monoclonal antibody (P256) Fab', 242(A)
$^{99}Tc^{m}$ nanocolloid and ^{111}In leucocyte scintigraphy in inflammatory bowel disease, 236(A)
$^{99}Tc^{m}$-tin colloid labelling of white blood cells in plasma, 373(A)
The treatment of myeloproliferative disease with ^{32}P, 377(A)
The use of platelets labelled with $^{99}Tc^{m}$-HMPAO for the diagnosis of suspected thrombosis, 375(A)
The use of $^{99}Tc^{m}$ hexametazime labelled leucocyte chemotaxis (in vitro) quantitation in rheumatology, 267(A)
Use of $^{99}Tc^{m}$ nanocolloid for locating inflammatory bowel disease and abdominal abscesses, 237(A)

Kidney
A multiple regression analysis for accurate background subtraction in $^{99}Tc^{m}$-DTPA renography, 315
Apparatus for the measurement of total body protein using prompt neutron activation analysis, 251(A)
Comparison of renal perfusion and uptake indicies using $^{99}Tc^{m}$-DTPA and $^{99}Tc^{m}$-MAG_3 in renal transplant recipients, 264(A)
Comparison of $^{99}Tc^{m}$-mercaptoacetyltriglycine and ^{131}I-orthoiodohippurate in determination of effective renal plasma flow (ERPF), 99
Diagnostic potential of diuresis renography: limitations by the severity of hydronephrosis and by impairment of renal function, 51
Gallium-67 scintigraphy in the detection of infected polycystic kidneys in renal transplant recipients, 167
How accurate is DMSA scanning? An experimental study, 216(A)
Indirect radionuclide cystography – the coming of age, 457(E)
In vivo imaging and quantitation of renal transplant rejection using indium-111 labelled anti-lymphocyte and anti-MHC class I and II monoclonal antibodies in a rat model, 264(A)
Modified diuresis renography in suspected obstruction, 215(A)
Pathophysiology of Cyclosporin nephrotoxicity, 265(A)
Quantitative static and dynamic renal scintigraphy with diuresis stimulation in renovascular hypertension, 795
Radioisotopic evaluation of renal function in liver transplant patients on Cyclosporin, 265(A)
Renal imaging with $^{99}Tc^{m}$-labelled DMSA in the detection of acute pyelonephritis: an experimental study in the pig, 63
Reproducibility of quantitative $^{99}Tc^{m}$-MAG 3 measurements in rats, 431
Screening for renovascular hypertension using captopril $^{99}Tc^{m}$-DPTA scintigraphy, 215(A)
The delayed renogram: its use in the assessment of upper urinary tract obstruction, 214(A)
The value of parenchymal transit time index (PTTI) in evaluation of surgery in obstructive uropathy (OU), 215(A)
Validity of the mean parenchymal transit time as a screening test for detection of functional renal artery stenosis in hypertensive patients, 807
$^{99}Tc^{m}$-MAG_3, mercapto acetyl triglycine, used for routine renal radionuclide studies, RRS, 263(A)
$^{99}Tc^{m}$-MAG_3 for quantitation of differential renal function, 759
UK gamma camera renography survey, 214(A)

Liver and spleen
A comparison of liver-spleen ratios and uptakes obtained using planar and tomographic techniques, 309
A new method of determining portal flow fraction in normal and diseased livers, 249(A)
Biliary leakage after cholecystectomy, 230(A)
Clinical evaluation of angiotension II enhanced perfusion scintigraphy in metastatic liver disease, 557
Detection of focal nodular hyperplasia of the liver by hepato-biliary scintigraphy, 227(A)
Diagnostic radionuclide imaging in amyloidosis, 219(A)
DISIDA kinetics measure liver function in dogs, 435
Evaluation of enhanced perfusion scintigraphy in metastatic liver disease, 369(A)
Gallbladder contraction; CCK or a fatty meal?, 229(A)
Hepatobiliary scintigraphy with third generation hidas in a specialized surgical unit, 228(A)
Re-evaluation of hepatic index in biliary atresia, 228(a)

99TcM-IODIDA in the dynamic assessment of hepatobiliary function in biliary obstruction, 228(A)
The effects of somatostatin on portal venous washout of a regionally adminstered marker, 227(A)

Lung

Diagnosis of thrombosis of the deep veins of the lower extremities and pelvis and pulmonary thromboemolism using $^{99}Tc^{m}$ human serum albumin macroaggregates, 141
Does $^{99}Tc^{m}$ human serum albumin alter the characteristics of nebulized pentamidine isethionate?, 523
Lung ventilation scintigraphy with an ultra fine aerosol (Technegas); a comparison with $^{81}Kr^{m}$, 257(A)
Quantitative evaluation of disease activity in sarcoidosis using a computerized ^{67}Ga index, 256(A)
Sites of deposition of aqueous aerosols: a study of efficiency of delivery systems for lung ventilation imaging in man, 171
$^{99}Tc^{m}$-Technegas for lung ventilation imaging: initial experience and comparison with krypton-81m, 257(A)
The noninvasive diagnosis of obliterative bronchiolitis following heart-lung transplantation, 213(A)
The particle size distribution of technegas and its influence on regional lung deposition, 425

Oncology

Absorbed dose estimates for ^{131}I-MIBG in neuroblastoma, 225(A)
Analogs of alpha-aminoisobutyric acid with various alkyl groups as potential tumour imaging, 751
Antibody labelling with $^{99}Tc^{m}$, 245(A)
A study of the pharmacokinetics, biodistribution and dosimetry of $^{99}Tc^{m}$(V)-dimercaptosuccinic acid, 238(A)
Blood and tissue kinetics of radiolabelled anti-CEA monoclonal antibody and F(ab)2 and Fab fragments in nude mice with human tumour xenografts: implications for tumour imaging and radioimmunotherapy, 585
Bone marrow scintigraphy in breast cancer, 389
Bone secondaries in breast cancer; the solitary metastasis, 235(A)
Bone marrow scintigraphy with $^{99}Tc^{m}$-nanocolloids in patients with maligant disease; a preliminary report, 374(A)
Bone scintigraphy following ^{89}Sr palliation of disseminated prostatic carcinoma, 234(A)
Clinical evaluation of angiotension II enhanced perfusion scintigraphy in metastatic liver disease, 557
Clinical use of a radiation detecting probe for the intra-operative localization of colorectal cancers and metastases, 222(A)
Colorectal cancer radioimmunoscintigraphy, RIS, with a $^{99}Tc^{m}$-labelled monoclonal antibody, PR1A3, 221(A)
Diagnosis and treatment of neuroblastoma using meta-iodobenzylguanidine (MIGB), 225(A)
Early effects of intra-arterial chemotherapy in patients with brain tumours studied with PET: preliminary results, 779
Evaluation of enhanced perfusion scintigraphy in metastatic liver disease, 369(A)
Follow-up of patients post-therapy with ^{131}I-MIBG, 225(A)
Gastro intestinal cancer localization with ^{111}In-labelled monoclonal antibodies (MoAb): can ^{111}In chelating agents improve the results obtained?, 246(A)

Imaging of small cell carcinoma using ^{131}I-labelled antibodies to vasopressin associated human neurophysin (VP-HNP), 643
Immunoscintigraphy (IS) in patients with colorectal cancer recurrences, 222(A)
Immunoscintigraphy with a new ^{111}In-labelled monoclonal antibody (OV-TL 3) in ovarian cancer, 223(A)
Intraperitoneal ^{131}I- and ^{111}In-791T/36 monoclonal antibody in recurrent ovarian cancer: imaging and biodistribution, 577
Intraperitoneal Yttrium-90 labelled monoclonal antibody in ovarian cancer, 226(A)
Investigations of brain tumours with ^{99}Tc^{m}-HMPAO SPECT, 325
Iodine-131 meta-iodobenzylguanidine (^{131}I-MIBG) for the localization of suspected phaeochromocytoma, 467
New tracers for the imaging of the medullary thyroid carcinoma, 285
Pre- and post-treatment distribution pattern of ^{123}I-MIBG in patients with phaeochromocytomas and paragangliomas, 567
Pretargeted immunoscintigraphy in patients with streptavidin conjugated antibody and radiolabelled biotin, 240(A)
Radioimmunoscintigraphy with ^{111}In labelled monoclonal antibody fragments (F(ab')$_2$2 BW431/31) against CEA: radiolabelling, antibody kinetics and distribution, findings in tumours and non-tumour patients, 627
Strontium-89 therapy in disseminated prostatic carcinoma, 224(A)
^{99}Tc^{m}-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results, 345
^{99}Tc^{m}-labelled meso-HMPAO and glutathione content of human lung tumours, 502
^{99}Tc^{m}(V)-DMSA imaging: does it have a role in the management of patients with head and neck SCC?, 239(A)
^{99}Tc^{m}(v) DMSA planar scintigraphy – does it have a role in the management of patients with head and neck squamous carcinoma?, 859
Therapeutic consideration in use of intraperitoneal radiolabelled monoclonal antibodies in ovarian carcimona, 149
What is the optimal imaging time for ^{99}Tc^{m} (v) DMSA planar scintigraphy in the detection of squamous carcinoma?, 741

Radiation protection

Absorbed dose estimates for ^{131}I-MIBG in neuroblastoma, 225(A)
A low cost system for the dispensing and administration of sodium iodide ^{131}I therapy solutions, 259(A)
A postal survey of quality assurance in nuclear medicine imaging in the UK during 1988, 181
A review of the secretion of radioactivity in human breast milk: data quantitative analysis and recommendations, 15
A standard protocol for the exchange of nuclear medicine image files, 703
Body surface dosimetry following re-injections of ^{111}In-leucocytes, 497
Breast milk – still more data required, 777(E)
Changes in dose limitation, 1(E)
Checklists for quality assurance and audit in nuclear medicine, 595
Computerized radioisotope timing of lower limb angiography, 240(A)
Dosimetry of an indium-111 anti-T lymphocyte monoclonal antibody in a rat model and its implication in man, 246(A)
Foetal risks following antenatal radionuclide administration, 79
Nuclear medicine: a safe occupation during pregnancy?, 260(A)
Nuclear medicine software: safety aspects, 535(E)

Preliminary data obtained using a new densitometry methodology, 372(A)
Quality assurance in nuclear medicine, 139
The BNMS survey of the secretion of radiopharmaceuticals in breast milk, 252(A)
Training in radiation protection for those physically directing medical exposures (nuclear medicine), 531(C)
What is the radiation hazard in nuclear medicine waiting rooms?, 252(A)

Radiopharmacy

A comparison of three methods to determine the radiochemical purity of $^{99}Tc^{m}$-HMPAO, 733
Analogs of alpha-aminoisobutyric acid with various alkyl groups as potential tumour imaging agents, 751
Antibody labelling with $^{99}Tc^{m}$, 245(A)
^{123}I labelling of phenothiazinium dyes for parathyroid localization, 243(A)
I-123: the isotope of the future?, 218(A)
Is $^{99}Tc^{m}$ hexamethyl-propyl-enamine oxime uptake in the tissues related to glutathione cellular content?, 905
Myocardial perfusion imaging in man using new $^{99}Tc^{m}$-labelled diphsophine complexes, 245(A)
Neutrophil activation during cell separation procedures, 901
Novel $^{99}Tc^{m}$ nitrosyl complexes as potential radiopharmaceuticals, 247(A)
$^{99}Tc^{m}$-diastereomeric dimercaptosuccinic acid complexes: comparison of their biodistribution, 449
The economical use of $^{99}Tc^{m}$-hexamibi kits, 247(A)
The use of $^{99}Tc^{m}$ hexametazime labelled leucocyte chemotaxis (in vitro) quantitation in rheumatology, 267(A)
Thoracic tissue thickness, blood and interstitial tissue thickness in pulmonary sarcoidosis, 370(A)
Use of sodium iodide to overcome the eluate age restriction for CeretecTM reconstruction, 29

Tomography/instrumentation/computing

A comparison of liver-spleen ratios and uptakes obtained using planar and tomographic techniques, 297
A new method of assessing forward ejection fraction from first pass radionuclide studies, 212(A)
A new method of determining portal flow fraction in normal and diseased livers, 249(A)
A multiple regression analysis for accurate background subtraction in $^{99}Tc^{m}$-DTPA renography, 315
An assessment of the role of ^{123}I-N-isopropyl-p-iodoamphetamine with single-photon emission computed tomography in the diagnosis of stroke and Alzheimer's disease, 271
A new syringe for bolus injection, 530(A)
Apparatus for the measurement of total body protein using prompt neutron activation analysis, 251(A)
A prototype coincidence counting probe, 251(A)
Assessment of the effect of interpolative background subtraction methods on the quantitation of myocardial uptake of $^{99}Tc^{m}$-MIBI using software phantoms, 249(A)
A technique for the use of standard outlines for attenuation correction and quantification in SPECT, 248(A)
A technique for using CT images in attenuation correction and quantification in SPECT, 83
A transputer based tomography display, 250(A)
Clinical use of a radiation detecting probe for the intra-operative localization of colorectal cancers and metastases, 222(A)

Comparison of two interpolative background subtraction methods using phantom and clinical data, 121
Considerations for improving the performance of dual photon bone absorptiometers, 221(A)
Educating the 'analogue consultant' to accept digital images, 260(A)
Factorial analysis of dynamic lymphoscintigraphy in lower limb lymphoedema, 109
Five patients with Rasmussen's syndrome investigated by single-photon-emission computed tomography, 5
How important is the amplitude image in cardiac phase/amplitude imaging?, 212(A)
Image reconstitution using energy information: convergence criteria, 248(A)
Investigations of brain tumours with $^{99}Tc^{m}$-HMPAO SPECT, 325
Low sensitivity of parathyroid scintigraphy for upper pole adenomata and a new subtraction method to improve their detectability, 220(A)
Methods of background subtraction in myocardial perfusion imaging with thallium-201: a comparative study in the presence of an artefact, 415
Nuclear medicine software: safety aspects, 535(E)
Patient positioning for intermodality studies, 259(A)
Quantitative 3-D PET with a multiwire proportional chamber positron camera (MUP-PET), 250(A)
Results from the first 212 patients studied using QDR bone densitometry, 217(A)
Semi-automatic quantification of regional cerebral perfusion in dementia using $^{99}Tc^{m}$-HMPAO and single photon emission tomography, 254(A)
Software design for computer controlled miniature scintillation detectors, 248(A)
The effect of ROI size and plane of reconstruction on HMPAO/SPET rCBF studies, 253(A)
The future of PET?, 621(E)
The multislice cylinder: a new approach to quantification of cardiac single photon emission tomography, 409
The modulation transfer function (MTF): a valuable tool for routine QC, 251(A)

Vascular

An in vitro model for the scintigraphic detection of thrombi using a $^{99}Tc^{m}$-labelled antifibrin monoclonal antibody, 653
Autologous LDL labelling for characterization of human atherosclerotic lesions, 208(A)
Combined papaverine test and penile blood flow in the investigation of impotence, 242(A)
Computerized radioisotope timing of lower limb angiography, 240(A)
Detection of experimental atherosclerosis with ^{111}In radiolabelled hematoporphyrin derivative, 841
Diagnosis of thrombosis of the deep veins of the lower extremities and pelvis and pulmonary thromboemolism using $^{99}Tc^{m}$ human serum albumin macroaggregates, 141
Factorial analysis of dynamic lymphoscintigraphy in lower limb lymphoedema, 109
Fluid and electrolyte changes in premenstrual syndrome, 219(A)
Gamma camera measurement of limb blood flow to resolve diagnostic problems in vascular surgery, 241(A)
Imaging venous thrombus in the post-operative patient using ^{111}In P-256 Fab1 monoclonal antibody, 375(A)
^{111}In platelet deposition following peripheral arterial thrombolysis, 376(A)
Iodine-131 meta-iodobenzylguanidine (^{131}I-MIBG) for the localization of suspected phaeochromocytoma, 467
Microvascular permeability after bone marrow transplantation (BMT), 378(A)
Noninvasive measurement of microvascular permeability to small solutes, 513
Radionuclide methodology for the assessment of the microcirculation in island pedicle flaps in a sheep model, 827

Regional microvascular permeability using dual isotope scintigraphy, 871
Sequential imaging of post-operative thrombus with a platelet specific monoclonal antibody (P256) Fab', 242(A)
The use of radionuclide imaging in subclavian vein occlusion following temporary venous access, 241(A)

Miscellaneous

An alternative use for the squat view, 262(A)
British Nuclear Medicine Society 17th Annual Meeting, 201(E)
Checklists for quality assurance and audit in nuclear medicine, 595
Detection of muscle necrosis in dermatomyositis by ^{111}In-labelled antimyosin Fab fragments, 603
Diagnostic radionuclide imaging in amyloidosis, 219(A)
Employment trends in nuclear medicine, 260(A)
Indium-111 monoclonal anti-myosin antibody in assessing skeletal muscle damage in trauma, 661

Author index

ABDEL-DAYEM, H.M., 99, 215, 477, 661, 669, 905
ABU-ZIDAR, F., 215
ACKERY, D., 369
AENGEVAEREN, W., 207
AGNEW, J.E, 425
AHMAD, M.,
AHMED, A., 209
AIAD, S.E., 208
AL-BAHR, R., 99
AL-GHUSSAIN, N.M., 827
AL-NAHHAS, A., 807
ALEEM, N., 685
ALLEN, S., 486, 741
ALLISON, M.E.M., 372
ANDREW, S.M., 585
ANGELBERGER, P., 209, 414
ARIMORI, S., 191, 817
ARNOLD, A.J., 216
ASSAYAG, P., 539
ATLAN, H., 409
AVISON, M.P., 381
AWH, O.D., 449
BABICH, J., 621
BADRUDOZA, M., 669
BAHAR, R.H., 215
BAILEY, D.L., 703
BAILEY, J., 871
BALDWIN, R.W., 577, 585
BALLARDIE, F.W., 378
BANIC, A., 827
BARES, R., 627
BARKER, F., 373
BARSOTTI, J., 109
BATEMAN, N.T., 523
BAYNE, V.J., 29
BAULIEU, F., 109
BAULIEU, J.L., 109
BAUM, R.P., 345
BELL, D., 901
BELTON, I.P., 214
BENTLEY, S.J., 221
BERGMANN, H., 703
BERRIDGE, D.C., 376, 378, 487
BESSENT, R., 369, 557
BESSER, G., 567
BESTAGNO, M., 285
BOCK, W.J., 325
BOK, B., 539
BOMANJI, J., 567, 807
BOSSOYT, A., 603
BOURGEOIS, P., 389
BRADNAM, M., 369, 557
BRIGGS, B.A., 370
BRITTON, K.E., 149, 205, 211, 212, 215, 221, 567, 807
BROADHURST, P., 211
BROCHET, E., 539
BROWN, P.M., 841
BROWNELL, A.-L., 891
BROWNLEE, B., 62
BROWNLESS, S.M., 216
BUELL, U., 627
BUIJS, W., 220
BURKE, J.F., 217, 503
BUSEMANN-SOKOLE, E., 703
BUXTON-THOMAS, M. 208
CAMPBELL, F.C., 193
CAMPS, J., 1653
CARELSEN, O., 1879
CAREY, L.C., 435
CARTY, H.M., 216
CASEY, M., 373
CASHMAN, P., 211
CHALLENOR, V.F., 371
CHAMBRON, J., 723
CHAN, H.M., 221
CHANDLER, S.T., 297, 371
CHOKSEY, M.S., 603
CHORARIA, S.K., 401
CLARK, A.R., 523
CLARKE, S.E.M., 166, 486, 741, 859
CLEGG, J., 551
CLEYNDERT, P., 653
COAKLEY, A.J., 15, 139, 201, 220, 497, 791
COLDITZ, G.A., 271
COLLINS, R.E.C., 220, 791
COTTINGHAM, R.L., 213
COOPER, B., 643
COOPER, I., 208
COOPER, J., 63
CORSTENS, F., 207, 220
COSGRIFF, P.S., 214, 535
COSTA, D.C., 207, 459, 603
COUTTS, C.T., 171
CRADDUCK, T.D., 703
CRAIG, A., 212
CRITCHLEY, M., 377
CROCKARD, H.A., 603
CRONIN, B., 503
CROWTHER, M.E., 149
CULLEN, P.T., 193
CULLUM, I., 216, 372
CUMMINS, B., 371
CUMMINS, P., 371
CUSCHIERI, A., 193
DABIENS, UJ., 109
DACIES, J.E., 807
DADAH, M., 661
DANPURE, H.J., 375
DAVIDSON, B.R., 222
DAVIES, I.H., 315
DAVIES, M.C., 217
DAVIES, J.M., 377
DAVIES, S., 871
DAWES, J., 901
DE BOER, H., 220
DEBEUCKELAERE, S., 603
DE CONINCK, A., 603
DE CONNINCK, F., 703
DE GEETER, F., 603
DELEU, D., 603
DEMOTS, H., 841
DENDY, P.P., 171
DE SCHRIJVER, M., 218
DEVIS, G., 161
DIAMOND, P.D., 215
DIGE-PETERSEN, H., 353
DINSTL, M., 222
DUFFY, G., 373
DYKE, L., 205, 211, 212
DYMOND, D.S., 205, 211, 212
EDWARDS, E.C., 215
ELGAZZAR, A.H., 477, 661
ELL, P.J., 207, 209, 216, 217, 372, 459, 603
ELLIOTT, A.T., 377
ELLISON, E.C., 435
EL-SAYED, M., 99, 477, 661

EL-SHIRBINY, A.M., 905
ELSTOB, J., 205
ENGLISH, R., 5
ENCKE, A., 345
FARAGGI, M., 539
FASS, J., 627
FEENER, J., 557
FEINENDEGEN., L.E., 325
FEITSMA, R.I.J., 653
FENNER, J., 369
FEREMANS, W., 389
FERGUSON, G.H., 370
FERNANDO, O., 167
FLEMING, J.S., 83
FLINT, J., 699
FLORENTZ, P., 723
FLUEKIGER, F., 795
FOGELMAN, I., 765
FOLAMI, A.O., 221
FORSTER, A.M., 29
FRANCIS, J.T., 214
FRASER, I.A., 222, 435
FRIER, M., 376, 378, 487
FROIDEVILLE, J.L., 431
FRUHLING, J., 389
FUEGER, G.F., 795
GARCIA, A., 415
GARVIE, N.W., 160
GASSAVELIS, C., 389
GEORGE, P., 513
GIE, C., 577
GIUBBINI, R., 285
GODLEY, M.L., 63
GOLDBERG, J.A., 369, 557
GONZALEZ, F.M., 759
GOPINATH, P.G., 679
GORDON, B., 335
GORDON, I., 457
GORMAN, C.A., 768
GOTSMAN, M.S., 409
GRANOWSKA, M., 149, 221
GRAY, J.M., 370
GRAY, L.L., 841
GRAY, W.H., 372
GRUCKER, D., 723
GUERRA, U.P., 285
GUPTA, K., 679
HAEGEL, A., 539
HALL, M.L., 216, 217, 372
HAM, H.R., 161, 431
HARDING, L.K., 77, 181, 376, 383, 408, 530, 531, 595, 777
HARDY, J.G., 45
HARRIS, P., 567
HARRISON, R., 375
HART, G.C., 381
HASSAN, I.M., 669
HAUSEGGER, K., 795
HAWKER, R.J., 374
HAWKINS, L.A., 221
HAWKINS, P.N., 219
HAY, I.D., 768
HAYES, A.A., 768
HEDUAN, E., 523
HERTEL, A., 345
HERZOG, H., 325, 779
HESSLEWOOD, S.R., 77, 296, 376
HIGGENBOTTAM, T.W., 171
HIGLEY, B., 503
HILDITCH, T.E., 377
HILSON, A.J.W., 167, 215
HINGE, D., 211
HIRSH, V., 643
HISADA, K., 751
HOCKADAY, J.M., 5
HOLCOMB, H.H., 335
HOLT, P.M., 210
HOPKINSON, B.R., 376, 378, 487
HOR, G., 345
HOUGHTON, A.D., 486
HOULE, S., 733
HOUSTON, A.S., 121, 212
HOWS, J.M., 378
HUMAYUN, M.S., 335
HUSSAIN, S.Y., 219
HUTTON, B.F., 703
HUTTON, I., 35, 205, 213
IANNOTTI, F., 603
ICHIKAWA, Y., 191
IIVANAINEN, M., 891
INAM-UR-REHMAN, A., 685
ITTI, R., 109
JACKSON, M.H., 901
JACOBS, H.S., 217
JAFFE, S., 409
JAHAN, S., 477
JAIN, D., 205
JANSEN, J.B.M.J., 715
JARRITT, P.H., 209, 459
JEGHERS, O., 431
JIMENEZ-HEFFERNAN, A., 759
JONCKHEER, M., 161
JOOMAN, S., 221
JOOSTEN, H.J.M., 715
JUVELLS, I., 415
KAPOOR, M.M., 679
KEEGAN, J., 871
KENNEDY, N.S.J., 193
KERR, D.J., 557
KETTLE, A.G., 220, 791
KILLEN, A.R., 271
KIM, J.R., 449
KINGSTONE, D., 219
KIWIT, J.C.W., 325, 779
KLETTER, K., 51
KLOPPENBORG, P., 220
KLOSSOCK, J., 375
KOURIS, K., 215, 669, 827
KROISS, A., 222
KUWERT, T., 325, 779
LAFRANCE, N.D., 335
LAHIRI, A., 205, 211
LAMERS, C.B.H.W., 715
LANGEN, K.-J., 325, 779
LAUNES, J., 891
LAVENDER, J.P.; 219
LAVENDER, P., 375
LAWAETZ, O., 353
LAWSON, R.S., 215
LAZARUS, C., 486, 741, 859
LEVY, R.D., 205
LEWINGTON, V., 369
LEWIS, D.H., 827
LIEPINS, P., 486
LIEWENDAHL, K., 891
LINDROTH, L., 891
LISBONA, R., 643
LLAMAS-ELVIRA, J.M., 759
LOATS, H., 335
LONG, D.M., 335
LORENZ, M., 345
LUI, D., 459
LUI, S., 167
LUPATTELLI, G., 208
MACDOUGAL, I.R., 855
MAH, G., 733
MACKINTOSH, A.F., 206

MACLEOD, M.A., 212
MAHER, E., 215
MAHMOUD, A., 477
MAHMOUD, S., 661
MAIRA, G., 285
MAISEY, M.N., 210, 741, 765, 859
MAJEED, Q., 210
MAKIN, G.S., 376, 378, 487
MALINOW, M.R., 841
MALKI, A.A., 477, 661
MALTBY, P., 377
MARCUS, A.J., 807
MARIJA, R., 141
MARKSMAN, R.A., 577
MARLARME, M., 389
MARTIN, W., 35, 205, 213
MARTINEZ-PAREDES, M., 759
MASON, R., 486
MATEO, A., 759
MATHER, S., 149, 221
MAUGHAN, J., 401, 551
McARDLE, C.S., 369, 557
McCREADY, V.R., 503, 621
McGHIE, I., 35
McKEE, R.F., 369, 557
McKILLOP, J.H., 77, 181, 311, 365, 369, 372, 557, 595
McLEAN, A., 215
MELIKIAN, V., 376
MESSIAN, P., 539
METCALFE, M.J., 206
MIDDLETON, G.W., 315
MILLAR, A.M., 901
MILLAR, B.W., 193
MILLS, J., 401
MIODRAG, O., 141
MITCHELL, D., 523
MITTAL, R.B., 209
MOHAMMED, M.M.J., 669
MOJIMINIYI, O.A., 374
MOLE, D.R., 171
MOORHEAD, J., 167
MORGAN, A., 315
MORI, H., 751
MOUNTFORD, P.J., 15, 79, 497, 777
MUELLER-BRAND, J., 209
MUNDY, M.J., 45
MURPHY, B., 221
MURPHY, G., 375
MURRAY, G.D., 387
MUZIK, O., 779
NAGAO, T., 817
NAJM, Y.C., 210
NEUMAYR, A., 222
NICOLETTI, R., 795
NIEUWENHUIZEN, W., 653
NIKKINEN, P., 891
NIMMON, C., 215, 807
NOELPP, U., 703
NORTH, W.G., 643
NORTHOVER, J.M.A., 221
NORTON, N.Y., 206
NUNAN, T.O., 208, 523
NURNBERGER, N., 51
O'BRIEN, P.M.S., 219
O'DOHERTY, M.J., 523, 791
OLIVER, R.M., 370
OMAR, Y.T., 477
OSMAN, S., 375
OSTER, G., 271
OSWALD, T., 723
OTT, R.J., 621
OWUNWANNE, A., 661, 905
PAGE, C., 523
PAGLIAINI, R., 285
PADHY, A.K., 679
PARKHOUSE, H.F., 63
PALAC, R.T., 841
PATEL, M.P., 551
PAUWELS, E.K.J., 653
PAVIA, J., 415
PEARS, D., 371
PEPPER, J., 503
PEPYS, M.B., 219
PERKINS, A.C., 487, 509, 577
PESL, H., 208
PETERS, A.M., 375, 378, 513
PETERS, M., 375
PETERS, O., 161
PFISTERER, M., 209
PHILLIPS, R.K.S., 221
PIEPSZ, A., 161, 431
PILCHER, J., 401
PIMM, M.V., 577, 585
PIPER, R., 221
PIROTTE, R., 218
PIZZOCARO, C., 285
POGGLITSCH, H., 795
POWELL, N.P. 503
PRESTY, S.K., 335
QAISAR, S., 685
RAFTERY, E.B., 205, 211
RANGASWAMY, M., 679
RANSLEY, P.G., 63
RAUSHCA, F., 208
RAZZAK, S., 477
REED, N.S., 377
REES, M.R., 206
REILLY, R.M., 733
REQUENA, M.J., 759
RICHMAN, P., 221
RIEU, P.N.M.A., 715
RISDON, R.A., 63
ROBERTS, P.J., 1
ROLAND, J., 161
ROOSEN, N., 325, 779
ROS, D., 415
ROSE, M.R., 370
ROSS, G., 567
ROTA KOPS, E., 779
ROUSE, J.R., 217
RUDD, R., 871
RUSSELL, G.J., 371
RYDER, J.P., 216, 372
SADEK, S., 99, 905
SAHBA, M., 99, 215
SAHWEIL, A., 477
SAMPSON, C.B., 496
SAMPSON, W.F.D., 121
SCHLUMPELICK, V., 627
SCHMITT, H.E., 209
SCHULLER, J., 222
SCHULZ, J., 643
SCHWARZ, A., 345
SECCHI, V., 109
SEDDON, D.J., 370
SHAFFER, P., 435
SHANKER, R.G., 374
SHARP, P.F., 535
SHEARD, K.L, 206
SHEPHERD, J.H., 149
SHEPSTONE, B.J., 5, 374, 467
SHIBA, K., 751
SHIM, S.C., 449
SHORT, M.D., 222
SHUKLA, N.K., 679
SIMPSON, H.K.L., 372
SINCLAIR, A.J., 567
SINHA, A.K., 459

SINZINGER, H., 208, 414
SIRAJ, Q.H., 685
SLEVIN, M.L., 149
SMITH, N.B., 530
SMITH, T., 205
SMITS, P., 207
SNASHALL, P.D., 370
SNYDER, S.H., 409
SOBNACK, R., 205, 221
SOLANKI, R., 205
SOMERS, G., 603
SOPENA, R., 759
SOPER, N., 5, 374, 467
SOWTON, E. 210
STAUBAS, A.E., 435
STEVAN, M., 141
STOCKDALE, H.R., 216
STONE, D.L., 409
STORES, G., 5
STUTTLE, A., 375
SURESH, L., 905
SUTTON, D.G., 193
SUZUKI, Y., 191, 817
SWANTON, R.W., 209
SWENY, P., 167, 215
SYKES, D.A., 376
SYMONDS, E.M., 577
SZILVASI, I, 221
TAKAYA, M., 191
TAYLOR, D.N., 222, 401, 551
TELFER, A.B.M., 372
TERZI, A., 285
TESTA, H.J., 215
THAKRAR, D.S., 215
THIEN, T., 207
THOMAS, S., 523
THOMSON, W.H., 315, 383, 530
THORLEY, P.J., 206
THORNBACK, J.R., 218
TICHELER, C., 220
TIMMIS, A.D., 210
TONDEUR, M., 431
TORRES, M., 759
TRUONG, S., 627
TSANG, V., 167
TUCHMANN, A., 222
TURNER, F.E., 841
TUTTLE, S., 435
TWEDDEL, A.C., 35, 205, 213
TYRRELL, D.A., 29, 374, 503
UNDERWOOD, S.R., 207
UPSDELL, S.M., 215
VALERE, P., 539
VAN KROONENBURGH, M.J.P.G., 715
VUKASIN, D., 141
WADDINGTON, W.A., 222
WAGNER, H.N., 335
WALLER, D.G., 371
WALTON, S., 206
WARD, B.G., 149
WARREN, H., 530
WARREN, M.J., 467
WASSER, M.N.J.M., 653
WASTIE, M.L., 376, 487
WATKIN, E.M., 214
WATKINSON, J.C., 741, 859
WATSON, M., 377
WEBB PEPLOE, M., 208
WEBBERLEY, M.J., 376
WEISS, A.T., 409
WEISS, W., 222
WELLS, C.P., 220, 791
WESTBY, J., 378
WILKINSON, P., 871
WILLIAMS, E.D., 181, 871
WILLIAMS, E.S., 207
WILSON, I., 206
WIRTH, M., 222
WISEMAN, M.N., 211, 212
WISON, C.G., 45
WONG, G.L.M., 733
WOOLMAN, P.S., 171
WRAIGHT, E.P., 190
YACOUB, M.H., 213
YACOUB, T., 905
YAMAUCHI, K., 191, 817
YOUNG, J., 215